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Abstract
Genomic medicine has greatly matured in terms of its technical capabilities but the diffusion of genomic innovations worldwide faces significant barriers beyond mere access to technology. New global development strategies are sorely needed for biotechnologies such as genomics and their applications towards precision medicine without borders.
Moreover, diffusion of genomic medicine globally cannot adhere to a "one-size-fits-allcountries" development strategy, in the same way that drug treatments should be customized. This begs a timely, difficult but crucial question: how should developing countries, and the resource-limited regions of developed countries, invest in genomic medicine? While a full-scale investment in infrastructure from discovery to the translational implementation of genomic science is ideal, this may not always be feasible in all countries at all times. A simple "transplantation of genomics" from developed to developing countries is unlikely to be feasible. Nor should developing countries be seen as simple recipients and beneficiaries of genomic medicine developed elsewhere because important advances in genomic medicine have materialized in developing countries as well. There are several noteworthy examples of genomic medicine success stories involving resource-limited settings which are contextualized and described in this global genomic medicine innovation analysis. Additionally, we outline here a new long-term development strategy for global genomic medicine in a way that recognizes the individual country's pressing public health priorities and disease burdens. We term this approach the "Fast-Second Winner" model of innovation that supports innovation commencing not only "upstream" of discovery science but also "mid-stream", building upon emerging highly promising biomarker and diagnostic candidates from the global science discovery pipeline, based on the unique needs of each country. A mid-stream entry into innovation can enhance collective learning from other innovators' mistakes upstream in discovery science and boost the probability of success for translation and implementation when resources are limited. This à la carte model of global innovation and development strategy offers multiple entry points into the global genomics innovation ecosystem for developing countries, whether or not extensive and expensive discovery infrastructures are already in place. Ultimately, broadening our thinking beyond the linear model of innovation will help us to enable the vision and practice of genomics without borders in both developed and resource-limited settings.
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Introduction
Genomic medicine is inherently a "science without borders", aiming to advance therapeutic and diagnostic medicine worldwide. The field has greatly matured over the last decade in terms of its technical capabilities. On the other hand, the vision and practice of genomics without borders face formidable challenges and opportunities beyond simply access to technology (McCarthy et al., 2013) . For example, an astute global and yet customized strategy for the diffusion of global genomics across nation state borders is lacking.
Diffusion of genomic medicine globally cannot adhere to a "one-size-fits-all" model, in the same way as drug treatments should be customized. This begs a timely, difficult but crucial question: how should developing countries, and the resource-limited regions of the developed countries, invest in genomic medicine?
One might argue that a full-scale infrastructure investment from discovery to the translational implementation of genomic science is ideal and should be in place in all countries worldwide. However, this may not always be feasible, with resource limitations; or, if achieved, scientific capacity building may not be real-time and commensurate with global innovative breakthroughs, thereby resulting in time lags and inequities in global science.
A simple transfer of genomic services from developed to developing countries is unlikely to be feasible. Developing countries should not be seen simply as recipients and beneficiaries of genomic medicine developed elsewhere because important advances in genomic medicine have been (and will continue to be) materializing in developing countries as well. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There are several noteworthy examples of genomic medicine success stories involving resource-limited settings, some of which will be contextualized and described in this global genomic medicine innovation analysis. Additionally, we outline here a new long-term development strategy for global genomic medicine in a way that recognizes the pressing public health priorities and disease burdens of the individual countries concerned.
We term this approach "Fast-Second Winner" model of biotechnology innovation without borders which broadens our approach to global innovation beyond a narrow linear model that invariably commences upstream from discovery science.
Where do we stand currently in global genomics? to facilitate, and at the same time rationalize, the translation of genomic and precision medicine interventions into the clinic. In principle, genomic and precision medicine are two separate but highly complementary disciplines, the former comprising an integral part of the latter. In other words, genomic medicine guides customization of healthcare, with medical decisions, practices or products being tailored to the individual patient mainly by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 means of molecular and cellular-based approaches but also in conjunction with imaging and other analytical approaches.
However, the pace of implementation of genomic medicine varies from country to country, depending upon a number of different parameters. These parameters include barriers, arising mainly from the lack of resources and infrastructure, poor technology and knowledge transfer, the limited genomics education of healthcare professionals and occasionally misplaced skepticism regarding the potential benefits that this new discipline has to offer medicine (Forero et al., 2016) . Additionally, most advances in human and medical genomics stem from resource-rich developed countries. Therefore, they can generally not be translated directly into the settings frequently found in resource-limited emerging countries. As such, the potential of genomic medicine is often not fully appreciated, whether by biomedical scientists and healthcare professionals, or by the general public and policymakers. When one takes into account that around 85% of the world's population lives in developing/resource-limited countries, it becomes apparent that the issue of providing access to genomic medicine in these settings is crucial.
Despite these barriers, there have been several notable examples of the successful implementation of genomic medicine projects in resource-limited settings across different continents that pertain either to population pharmacogenomics or public health genomics.
Moreover, there have been various successful efforts to build research networks with common interests in genomic medicine. Some of these are summarized below, and we believe that they can serve as model cases for the implementation of genomic medicine in other resource-limited environments. Herein, the notions "developing country" and "resource-limited settings" will be used to denote an environment in which: (a) resources assigned for genomics research are scarce, (b) access to genomics knowledge and information is restricted, (c) genomic implementation is limited, (d) genomics education is 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Capacity building in genomic medicine
One of the most important reasons that genomics research is lagging behind in resource-limited settings, as compared to developed countries, is the lack of dedicated resources and research centers that help to spearhead the generation of new knowledge by training and educating young scientists, medical students, clinicians etc.
Research in Africa has revealed insufficient genetic knowledge at the level of medical education, while international genetics research on Africa has consistently failed to build capacity in the two-decade post-initiation of the Human Genome Project (Wonkam et al., 2006 , Wonkam et al., 2011 , Matovu et al., 2014 . Since then, the latter trend is rapidly changing with initiatives such as the H3Africa Consortium that is fully engaging young Africa Sciences in Genomics Research (Consortium, 2014 , Matovu et al., 2014 The center intends to forge formal links with other universities and institutions through equitable memoranda of understanding. In the field of Genomic Medicine, the first project focusing on Public Health Genomics was designed and already started, in an effort to canvass the genomic medicine environment in the UAE with the prospect of extending this project into neighboring countries in the region (see below).
Population pharmacogenomics
Pharmacogenomics is steadily being implemented in the world's health systems albeit at a rather heterogeneous pace. European populations revealed significant differences in the prevalence of 7 pharmacogenomic biomarkers in at least 7 European populations, which are implicated in the efficacy and toxicity of 51 drugs. As far as warfarin dose recommendation is concerned, it is evident that there are marked differences in the predicted average warfarin dose in different European populations analyzed (Mizzi et al., 2016) . These data may help in amending existing treatment recommendations, and rationalizing treatment modalities for these drugs in the respective countries.
As of mid-2017, this project is being replicated, with a special focus on South East Asian populations, under the umbrella of the Global Genomic Medicine Collaborative (G2MC) Pharmacogenomics Working group and includes 8 South East Asian populations, mostly from developing countries ( Table 1) . The 100 Pharmacogene Resequencing Project will focus on the resequencing of 100 pharmacogenes in a large number of healthy In addition to the burden of Communicable disease such as HIV and malaria, nearly ¾ of newborns with Sickle Cell Disease (SCD) are born in Africa (Piel et al., 2013) indicating the urgent need in this setting to further accelerate research on pharmacogenomics, that could ultimately improve the prevention of disease and patient care. Fortunately, emerging genomics research involving African scientists are improving our knowledge of genomic modifiers of SCD, that will be useful for anticipatory guidance in clinical practice (Makani et al., 2011 , Wonkam and Hurst, 2014 , Geard et al., 2017 .
Rethinking the linear model of innovation for genomics without borders A Fast-Second Winner development strategy
The linear model of innovation has been a dominant framework that has guided and shaped scientists' and innovators' approach to scientific breakthroughs. The linear innovation model commences from discovery science and proceeds in a linear fashion toward translational research, in its various phases, then on to implementation science Building on the above context, and the fact that innovations and innovators can commence "innovating" not only upstream but also "midstream", we propose here a new long-term development strategy termed the "Fast-Second Winner" mode of innovation ( Fig. 1) .
The Fast-Second Winner model recognizes the pressing public health priorities and disease burdens of individual countries and supports midstream innovations that build upon emerging highly promising biomarker and diagnostic candidates from global science.
Importantly, a mid-stream entry into innovation can enhance collective learning from other innovators' mistakes upstream in discovery science and boost the probability of success for translational and implementation science when resources are limited. Hence, this à la carte model of global innovation offers multiple entry points into global genomics innovation ecosystem for developing countries, whether or not extensive discovery infrastructure is already in place.
This is contrary to investing in ALL aspects of innovation horizontally from discovery infrastructure to translation to implementation science in a given country, which is not only expensive but also does not serve well the unique needs of each country. Lastly, to be able to apply a second rapid model of innovation, one needs some kind of an innovation observatory, which can best identify the emerging candidate markers or drug would reduce the logistical burden and make it easier and more cost-effective for participants from developing countries to attend.
The above advances and considerations gave rise to the concept of the Golden Helix ® Conferences, as high level scientific summits focusing on themes pertaining to the fields of genomics, pharmacogenomics and personalized medicine. In brief, the Golden Helix ® Conferences aimed to advance genomics worldwide under three interlinked themes of interest to precision medicine without borders:
• The Golden Helix Symposia (http://symposia.goldenhelix.org) range in length from 2 to 4 days, with an average attendance of 450 participants (ranging from 250 to 900 participants). Conferences are usually held in an environment outside the mainstream settings that is conducive to multidisciplinary thinking and collaboration.
• The Golden Helix Pharmacogenomics Days (http://pharmacogenomicsdays.goldenhelix.org) are international educational event series organized in major cities with tertiary academic healthcare facilities.
The aim of this event is to provide timely updates on the field of pharmacogenomics to local biomedical scientists and healthcare providers.
Contrary to the Golden Helix Symposia, the Golden Helix Pharmacogenomics
Days have a more educational ethos, span between a half-day to a full day in length, and address on average 150 participants. Registration is free-of-charge, At the same time, the seamless incorporation of genomic medicine into clinical practice is hindered by insufficient genomics education, which is not uniformly provided in the various academic institutions worldwide (Mai et al., 2014 , Mitropoulou et al., 2014 , Pisanu et al., 2014 . 
Genomic Medicine and Public Health
Integration of genomics research findings into medicine is a multistep approach that depends upon several disciplines mostly related to public health. Such disciplines include addressing the ethical, social and legal issues pertaining to genomic medicine, assessing the educational needs of healthcare professionals, both at the undergraduate and postgraduate levels, as far as genomic medicine is concerned, and precisely mapping the environment of the stakeholders and decision makers that are involved in genomic medicine. In this latter case, there are several key players and stakeholders, whose genomics awareness and views vary significantly; hence, performing a systematic mapping Similarly, a Public Health Genomics project is planned, in parallel to the 100
Pharmacogene Resequencing Project in South East Asia (see above), and in partnership with the Golden Helix Foundation, so that the benefits of the pharmacogenomic analysis in these populations can be maximized. As with the related project already running in the UAE, this parallel project will include: (a) mapping the pharmacogenomics educational environment in the participating countries in South East Asia, and (b) raising pharmacogenomics awareness among healthcare professionals by organizing scientific conferences and other educational activities, similar to those described above.
Regrettably, in Africa, the proportion of medical professionals with a thorough understanding of human and medical genomics is still relatively low. An attempt in subSaharan Africa to triangulate the views of multiple stakeholders related to prenatal diagnosis of SCD revealed several discrepancies that usefully inform future policy actions (Lebeko et al., 2016) .
Economics in Genomic Medicine
Genome-guided drug treatment modalities are expected to reduce national healthcare expenditure (Snyder et al., 2014) . To date, the scientific discipline of economic evaluation in genomic medicine, pharmacogenomics and public health genomics is still poorly (Fragoulakis et al., 2016 , Fragoulakis et al., 2017 , which, in addition to the already existing economic evaluation models in genomic medicine, will be of the utmost importance as innovative tools for performing cost-effectiveness analyses in such a rapidly evolving discipline.
Lastly, the issue of pricing and reimbursement in genomic medicine is a cornerstone for the incorporation of genomics into clinical medicine, given the lack of harmonization between pricing and reimbursement policies between European countries, contrary to the situation pertaining in the United States (Logue, 2003) . In Europe, very few countries (e.g. the Netherlands, the United Kingdom, Switzerland) reimburse genetic testing services, while other countries clearly lag behind. As such, the general strategy towards pricing and reimbursement for genomic medicine should first be outlined, providing an overview of the rationale and basic principles guiding the governance of genomic testing services, clarifying their objectives, and allocating and defining responsibilities among and between stakeholders, focusing on different EU countries'
healthcare systems.
Particular attention should be paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differ between various countries owing to differences in disease prevalence and public health relevance, et al., 2016) . Subsequently, it is hoped that a more technical analysis will lead to the introduction of a robust policy in relation to pricing and reimbursement in genomic medicine, thereby contributing to an effective and sustainable health-care system with benefits to the economy at large.
Building regional and global genomic medicine research networks
Synergizing efforts among researchers with common research interests from various parts of the world could significantly expedite efforts to bring genomic medicine, as with every other discipline, closer to fruition (Manolio et al., 2015) . Consistent with one of the stated goals of the GMA, namely the fruitful engagement between research groups from both developing and developed countries to study families with rare diseases or unique clinical features (especially countries with a higher incidence of consanguinity and/or well-defined founder populations), the GMA actively participates in the DRIFT (Discovery Research Investigating Founder Population Traits) Consortium. In early 2016, a call for research collaboration was made by the Regeneron Genetics Center (RGC) and the GMA, aimed specifically at developing countries. DRIFT aims to understand the genetic architecture of founder populations throughout the world with direct impact on human health and disease. The DRIFT Consortium aims to catalogue population-specific allelic architecture, with a view to understanding the biological and functional consequences of specific genomic variants identified, and to sharing best-practice approaches to relieve disease burden in these populations. Ever since its establishment, the expansion of the GMA membership base has progressed at a very rapid pace, currently comprising over 1,300 members from >70 international non-governmental organization that is working to ensure that all information on genetic variation and its effect on human health can be collected, curated, interpreted and shared freely and openly (Kaput et al., 2009) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There are also other important international efforts, such as the Global Alliance for
Genomics and Health (GA4GH; http://www.ga4gh.org), the Human Genome Organization (HuGO; http://www.hugo-international.org) and the Global Genomic Medicine
Collaborative (G2MC; http://www.g2mc.org). These organizations have various activities related to genomic and precision medicine, such as genomic data sharing (GA4GH), implementation of genomic medicine (G2MC), with activities that are also relevant to resource-limited countries. The activities of these organizations have been outlined
elsewhere and as such lie outside the scope of this article.
Discussion
The implementation of genomic medicine does not always progress at a uniform pace in all parts of the world. There are countries, like the United States and countries in Northern Europe, where genomic medicine is being implemented at a more rapid pace, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Chung et al., 2004 , Borchers et al., 2008 ) and the same is true for carriers of the HLA-B*5801 allele who may develop severe cutaneous adverse reactions (Hung et al., 2005) , when treated with allopurinol. In Taiwan, the value of pharmacogenomics in tailor-made therapeutics has been acknowledged and, following a large prospective clinical study that confirmed the benefit of HLA-B*1502 genotyping to identify subjects at genetic risk for the abovementioned conditions (Chen et al., 2011) , the Taiwanese government began to reimburse the genotyping costs as of 2010.
In South East Asia and in Thailand in particular (Ramathibodi Hospital; Bangkok), a pharmacogenomics card was adopted to summarize patients' HLA gene variant information to predict the risk of developing SJS/TEN. Such pharmacogenomics cards have also been used in other settings and clinical studies, such as the PREPARE study of the Ubiquitous Pharmacogenomics (U-PGx) Consortium (www.upgx.eu) and could be readily applied in the context of tailor-made therapeutics.
In the UAE, following pharmacogenomics research into the role of variants in the G6PD gene and their association with drug-induced hemolytic anemia (Bayoumi et al., 1996) and the prevalence of NAT2, CYP2D6, CYP2C9 and VKORC1 pharmacogenomic variant allele frequencies in the Emirati population (Woolhouse et al., 1997 , Qumsieh et al., 2011 , Fortina et al., 2014 , Al-Gazali et al., 2016 , Dubai Hospital was prompted to integrate pharmacogenomics information for chemotherapeutic agents, while the UAE Health Authority policy of reporting adverse drug reactions in the UAE currently requires 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Conclusions and Outlook
The implementation of genomic medicine in resource-limited environments can be a difficult and lengthy process, which could deprive less privileged populations of the benefits that genome-guided interventions have to offer. Given the scarcity or even lack of resources in developing countries, the implementation of genomic medicine can only be benefits for all parties involved. Not only will developing countries benefit from the various training opportunities that will be created in addition to knowledge transfer, but developed countries may benefit too, through participation in multicenter projects to study cases and individuals with unique clinical features and/or rare diseases (Cooper et al., 2014 , Manolio et al., 2015 .
On the implementation front, it would be highly beneficial for developing countries to prioritize their efforts towards implementing actionable genomic medicine interventions, including but not limited to pharmacogenomic tests, genetic testing for the highly prevalent inherited conditions, which differ dramatically around the world. Therefore, country-, population-and region-specific data and research are needed. At the same time, it seems reasonable for decision makers and policymakers to invest an equal amount of effort into expanding the public health aspects of genomic medicine interventions, such as (a) mapping the stakeholders' environment and their opinions and stance related to genomics, (b) enacting new legislation and measures to set out a legal framework for the provision of genetic services, so that quality is ensured and the general public and the patients are safeguarded, and (c) adopting guidelines for the reimbursement of genetic tests, based on related cost-effectiveness analyses.
Lastly, if for some countries, the acquisition of expensive genomic technology and equipment may seem unrealistic, investment in continuous genomics education of healthcare professionals and biomedical scientists would be far easier and with a short-to medium-term return on such investment. Continuous genetics education can be provided to certificates/diplomas will be obtained and also to undergraduate students, by harmonizing the university curriculum with those of other developed countries, which could be used as paradigm for this purpose. In all of the above, synergies should be sought not only with renowned academics and institutions from developed countries but also with entities from other developing countries that have successfully implemented genomic medicine interventions.
Human genomics promises to transform medical practice around the world. Much attention has been focused on developed countries where most research leading to
Genomic and Precision Medicine is performed. However, resource-poor developing countries also have the potential to adopt genomic medicine. Therefore, we strongly believe that the examples described in this article could be readily replicated by other countries with a view to expediting their transition to the genomic medicine era, by harmonizing their strategies and policies with those of various other national healthcare systems that already enjoy the tangible benefits of genomics. Clearly, the inclusion of other omics into Precision Medicine will further contribute to these developments.
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Please note that this model is not only based on wet-lab scientific aspects but also, and most importantly, applies to other public health-related process of implementing genomics in clinical practices that involve many different aspects (cost effectiveness analysis, education, local health priorities, etc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
